These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 17478737)

  • 1. Serum cellular fibronectin and matrix metalloproteinase-9 as screening biomarkers for the prediction of parenchymal hematoma after thrombolytic therapy in acute ischemic stroke: a multicenter confirmatory study.
    Castellanos M; Sobrino T; Millán M; García M; Arenillas J; Nombela F; Brea D; Perez de la Ossa N; Serena J; Vivancos J; Castillo J; Dávalos A
    Stroke; 2007 Jun; 38(6):1855-9. PubMed ID: 17478737
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma cellular-fibronectin concentration predicts hemorrhagic transformation after thrombolytic therapy in acute ischemic stroke.
    Castellanos M; Leira R; Serena J; Blanco M; Pedraza S; Castillo J; Dávalos A
    Stroke; 2004 Jul; 35(7):1671-6. PubMed ID: 15166391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High serum levels of endothelin-1 predict severe cerebral edema in patients with acute ischemic stroke treated with t-PA.
    Moldes O; Sobrino T; Millán M; Castellanos M; Pérez de la Ossa N; Leira R; Serena J; Vivancos J; Dávalos A; Castillo J
    Stroke; 2008 Jul; 39(7):2006-10. PubMed ID: 18436890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety profile of tissue plasminogen activator treatment among stroke patients carrying a common polymorphism (C-1562T) in the promoter region of the matrix metalloproteinase-9 gene.
    Montaner J; Fernández-Cadenas I; Molina CA; Monasterio J; Arenillas JF; Ribó M; Quintana M; Chacón P; Andreu AL; Alvarez-Sabín J
    Stroke; 2003 Dec; 34(12):2851-5. PubMed ID: 14605329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke.
    Montaner J; Molina CA; Monasterio J; Abilleira S; Arenillas JF; Ribó M; Quintana M; Alvarez-Sabín J
    Circulation; 2003 Feb; 107(4):598-603. PubMed ID: 12566373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MMP9 variation after thrombolysis is associated with hemorrhagic transformation of lesion and death.
    Inzitari D; Giusti B; Nencini P; Gori AM; Nesi M; Palumbo V; Piccardi B; Armillis A; Pracucci G; Bono G; Bovi P; Consoli D; Guidotti M; Nucera A; Massaro F; Micieli G; Orlandi G; Perini F; Tassi R; Tola MR; Sessa M; Toni D; Abbate R;
    Stroke; 2013 Oct; 44(10):2901-3. PubMed ID: 23908067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma metalloproteinase-9 concentration predicts hemorrhagic transformation in acute ischemic stroke.
    Castellanos M; Leira R; Serena J; Pumar JM; Lizasoain I; Castillo J; Dávalos A
    Stroke; 2003 Jan; 34(1):40-6. PubMed ID: 12511748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevated serum S100B levels indicate a higher risk of hemorrhagic transformation after thrombolytic therapy in acute stroke.
    Foerch C; Wunderlich MT; Dvorak F; Humpich M; Kahles T; Goertler M; Alvarez-Sabín J; Wallesch CW; Molina CA; Steinmetz H; Sitzer M; Montaner J
    Stroke; 2007 Sep; 38(9):2491-5. PubMed ID: 17673718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of edaravone, a free radical scavenger, on circulating levels of MMP-9 and hemorrhagic transformation in patients with intravenous thrombolysis using low-dose alteplase.
    Tsuruoka A; Atsumi C; Mizukami H; Imai T; Hagiwara Y; Hasegawa Y
    J Stroke Cerebrovasc Dis; 2014; 23(10):2894-2899. PubMed ID: 25282183
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased body iron stores are associated with poor outcome after thrombolytic treatment in acute stroke.
    Millan M; Sobrino T; Castellanos M; Nombela F; Arenillas JF; Riva E; Cristobo I; García MM; Vivancos J; Serena J; Moro MA; Castillo J; Dávalos A
    Stroke; 2007 Jan; 38(1):90-5. PubMed ID: 17138950
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Matrix metalloproteinase expression is related to hemorrhagic transformation after cardioembolic stroke.
    Montaner J; Alvarez-Sabín J; Molina CA; Anglés A; Abilleira S; Arenillas J; Monasterio J
    Stroke; 2001 Dec; 32(12):2762-7. PubMed ID: 11739970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prediction of malignant cerebral infarction by molecular brain barrier disruption markers.
    Serena J; Blanco M; Castellanos M; Silva Y; Vivancos J; Moro MA; Leira R; Lizasoain I; Castillo J; Dávalos A
    Stroke; 2005 Sep; 36(9):1921-6. PubMed ID: 16100032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Matrix metalloproteinase-9 as a marker for acute ischemic stroke: a systematic review.
    Ramos-Fernandez M; Bellolio MF; Stead LG
    J Stroke Cerebrovasc Dis; 2011; 20(1):47-54. PubMed ID: 21044610
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oxidative stress and matrix metalloproteinase-9 in acute ischemic stroke: the Biomarker Evaluation for Antioxidant Therapies in Stroke (BEAT-Stroke) study.
    Kelly PJ; Morrow JD; Ning M; Koroshetz W; Lo EH; Terry E; Milne GL; Hubbard J; Lee H; Stevenson E; Lederer M; Furie KL
    Stroke; 2008 Jan; 39(1):100-4. PubMed ID: 18063832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased Serum Alkaline Phosphatase as a Predictor of Symptomatic Hemorrhagic Transformation in Ischemic Stroke Patients with Atrial Fibrillation and/or Rheumatic Heart Disease.
    Liu J; Wang D; Li J; Xiong Y; Liu B; Wei C; Wu S; Lin J; Liu M
    J Stroke Cerebrovasc Dis; 2016 Oct; 25(10):2448-52. PubMed ID: 27425768
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early biomarkers of clinical-diffusion mismatch in acute ischemic stroke.
    Rodríguez-Yáñez M; Sobrino T; Arias S; Vázquez-Herrero F; Brea D; Blanco M; Leira R; Castellanos M; Serena J; Vivancos J; Dávalos A; Castillo J
    Stroke; 2011 Oct; 42(10):2813-8. PubMed ID: 21836082
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke.
    Higashida RT; Furlan AJ; Roberts H; Tomsick T; Connors B; Barr J; Dillon W; Warach S; Broderick J; Tilley B; Sacks D; ;
    Stroke; 2003 Aug; 34(8):e109-37. PubMed ID: 12869717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Accuracy of Serum Matrix Metalloproteinase-9 for Predicting Hemorrhagic Transformation After Acute Ischemic Stroke: A Systematic Review and Meta-Analysis.
    Wang L; Wei C; Deng L; Wang Z; Song M; Xiong Y; Liu M
    J Stroke Cerebrovasc Dis; 2018 Jun; 27(6):1653-1665. PubMed ID: 29598905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Asymptomatic hemorrhage after thrombolysis may not be benign: prognosis by hemorrhage type in the Canadian alteplase for stroke effectiveness study registry.
    Dzialowski I; Pexman JH; Barber PA; Demchuk AM; Buchan AM; Hill MD;
    Stroke; 2007 Jan; 38(1):75-9. PubMed ID: 17122437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute hyperglycemia and early hemorrhagic transformation in ischemic stroke.
    Paciaroni M; Agnelli G; Caso V; Corea F; Ageno W; Alberti A; Lanari A; Micheli S; Bertolani L; Venti M; Palmerini F; Billeci AM; Comi G; Previdi P; Silvestrelli G
    Cerebrovasc Dis; 2009; 28(2):119-23. PubMed ID: 19506370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.